 -- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 -- -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global integrated commercial strategies -- -- On track to announce topline data from pivotal Phase 3 trial in Bardet-Biedl and Alström syndrome s late in fourth quarter of 2020 or early in first quarter 2021 -- -- Plan to announce data from multiple cohorts in ongoing Phase 2 basket study early in first quarter 2021 -- BOSTON, Nov. 02, 2020 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq:RYTM, a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today reported financial results and provided a business update for the third quarter ended September 30, 2020. 